CompletedInterventionalPhase 4Updated Nov 19, 2008
Assessing Cosopt Switch Patients
ClinicalTrials.gov ID
NCT00273442
Lead Sponsor
Pharmaceutical Research NetworkOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
60
Last Update Posted
Nov 19, 2008Estimated
Start Date
Nov 2005
Completion Date
Apr 2007Actual
Brief Summary
To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.
Ocular Hypertension
Open-Angle Glaucoma
Exfoliation Syndrome
Glaucoma, Pigmentary
timolol maleate
dorzolamide/timolol maleate fixed combination
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension
the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM
visual acuity should be 20/200 or better in each eye
Exclusion Criteria:
contraindications to study drugs
anticipated change in systemic hypotensive therapy during the trial
use of any corticosteroids by any route in the three months immediately prior to Visit 2